Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access [Yahoo! Finance]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Yahoo! Finance
leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program and will provide an update on the Company's patient access programs, development across tumor types, and key priorities for 2026. The session will be moderated by Garo H. Armen, PhD, Founder, Chairman, and Chief Executive Officer of Agenus, and will conclude with a live Q&A. Featured Topics and Speakers Strategic Direction: Advancing BOT+BAL Garo Armen, PhD Founder, Chairman, and Chief Executive Officer, Agenus Dr. Armen will open the session by discussing Agenus' mission to harness the immune system across tumor types and the urgency of advancing new options for patients with historically treatment-resistant cancers. He will also outline key priorities for 2026 as momentum continues to build across the BOT+BAL program. Clinical Progress: Durability and Consistency Across Tumors Steven J. O'Day,
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient AccessBusiness Wire
- Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal CancerBusiness Wire
- Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized [Yahoo! Finance]Yahoo! Finance
- Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues RecognizedBusiness Wire
- Agenus receives $20M payment under Zydus Life Sciences collaboration [Seeking Alpha]Seeking Alpha
AGEN
Earnings
- 11/10/25 - Miss
AGEN
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/26/26 - Form 8-K
- 3/24/26 - Form 4
- AGEN's page on the SEC website